CNS Pharmaceuticals Gestione

Criteri Gestione verificati 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Rami Levin

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	6.2yrs
Durata media del Consiglio di amministrazione	1.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

CNS Pharmaceuticals reports Q2 results

Aug 15

Here's Why We're A Bit Worried About CNS Pharmaceuticals' (NASDAQ:CNSP) Cash Burn Situation

Dec 04

AMMINISTRATORE DELEGATO

Rami Levin (56 yo)

no data

Mandato

Mr. Rami Levin, M.B.A. Director of CNS Pharmaceuticals, Inc. from December 2025 and serves as its President & CEO since January 01, 2026. Mr. Levin served as President at Saniona AB (publ) since January 7,...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Christopher Downs	Chief Financial Officer	6.2yrs	US$621.05k	0.00048% $ 17.7
Sandra Silberman	Chief Medical Officer	no data	US$361.64k	0% $ 0
Rami Levin	President	no data	Nessun dato	Nessun dato
Donald Picker	Chief Science Officer	6.6yrs	Nessun dato	Nessun dato

6.2yrs

Durata media

63yo

Età media

Gestione esperta: Il team dirigenziale di CNSP è esperto e expertise (durata media dell'incarico 6.2 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Rami Levin	President	less than a year	Nessun dato	Nessun dato
Faith Charles	Independent Chairman of Board	3.1yrs	US$78.88k	0% $ 0
Roger Stupp	Scientific Advisory Panel	less than a year	Nessun dato	Nessun dato
Jeffry Keyes	Independent Director	7.6yrs	US$59.75k	0% $ 0
Bettina Cockroft	Independent Director	2.7yrs	US$52.88k	0% $ 0
Jerzy Gumulka	Independent Director	8.2yrs	US$50.93k	0.00032% $ 11.8
Amy Mahery	Independent Director	1.9yrs	US$46.83k	0% $ 0
Timothy Cloughesy	Scientific Advisory Panel	1yr	Nessun dato	Nessun dato
Mark Gilbert	Scientific Advisory Panel	1yr	Nessun dato	Nessun dato

1.9yrs

Durata media

56yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di CNSP non è considerato esperto (durata media del mandato 1.9 anni), il che suggerisce un nuovo consiglio.

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/01/09 13:27
Prezzo dell'azione a fine giornata	2026/01/09 00:00
Utili	2025/09/30
Utili annuali	2024/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

CNS Pharmaceuticals, Inc. è coperta da 5 analisti. 1 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
James Molloy	Alliance Global Partners
Matthew Cross	Alliance Global Partners
Bruce Jackson	Benchmark Company

CNS Pharmaceuticals Gestione

Criteri Gestione verificati 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

High number of new and inexperienced directors

CNS Pharmaceuticals, Inc., Annual General Meeting, Nov 17, 2025

CNS Pharmaceuticals, Inc., Annual General Meeting, Apr 30, 2024

CNS Pharmaceuticals, Inc. Appoints Amy Mahery to its Board of Directors

CNS Pharmaceuticals, Inc., Annual General Meeting, Sep 14, 2023

Bettina M. Cockroft Joins CNS Pharmaceuticals, Inc.'s Board of Directors

Recent updates

High number of new and inexperienced directors

CNS Pharmaceuticals, Inc., Annual General Meeting, Nov 17, 2025

New major risk - Financial position

CNS Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $4.996373 million.

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $14 million.

New major risk - Financial position

No longer forecast to breakeven

New minor risk - Profitability

New major risk - Revenue and earnings growth

New major risk - Share price stability

Forecast to breakeven in 2027

CNS Pharmaceuticals Receives Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $3 million.

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

CNS Pharmaceuticals, Inc. announced that it expects to receive funding from Cortice Biosciences Incorporated

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $5.2 million.

The Nasdaq Hearings Panel Grants the Requested Extension to CNS Pharmaceuticals Until August 12, 2024

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.98075 million.

CNS Pharmaceuticals, Inc. announced a financing transaction

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.3725 million.

New major risk - Share price stability

CNS Pharmaceuticals, Inc., Annual General Meeting, Apr 30, 2024

CNS Pharmaceuticals Receives Non-Compliance Letter Form Nasdaq

CNS Pharmaceuticals Provides Non-Compliance Update

CNS Pharmaceuticals, Inc. Appoints Amy Mahery to its Board of Directors

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

CNS Pharmaceuticals, Inc. Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy

New major risk - Negative shareholders equity

CNS Pharmaceuticals, Inc. Opens 46 Clinical Trial Sites Across the U.S., Italy, France, Spain, and Switzerland

Cns Pharmaceuticals, Inc. Announces Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (Gbm)

CNS Pharmaceuticals Receives Letter from Nasdaq Regarding Non-Compliance with Minimum of $2.5 Million in Stockholders’ Equity Requirement Pursuant to Nasdaq’s Listing Rule 5550(b)(1)

CNS Pharmaceuticals, Inc., Annual General Meeting, Sep 14, 2023

CNS Pharmaceuticals, Inc. Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

CNS Pharmaceuticals, Inc. Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme

Bettina M. Cockroft Joins CNS Pharmaceuticals, Inc.'s Board of Directors

CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Announces Investigator-Initiated Phase 1B/2 Trial to Be Conducted At the Pomeranian Medical University in Poland

Cns Pharmaceuticals, Inc. Appoints Faith Charles as Independent Member and as Chairperson of the Board of Directors

CNS Pharmaceuticals, Inc Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM)

CNS Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.

Insufficient new directors

CNS Pharmaceuticals, Inc. Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Provides A Clinical Update of Its Anti-Cancer Drug Candidates Currently in Development for the Treatment of Primary and Metastatic Brain and CNS Cancer

CNS Pharmaceuticals reports Q2 results

CNS Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2022

CNS Pharmaceuticals Inc. Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Announces Presentation of Ongoing Potentially Pivotal Berubicin Clinical Trial Design at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

Price target increased to US$10.00

Insufficient new directors

CNS Pharmaceuticals, Inc. Receives Approval from Competent Authority of Switzerland for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme

CNS Pharmaceuticals, Inc. announced that it expects to receive $11.500001 million in funding

Insufficient new directors

Here's Why We're A Bit Worried About CNS Pharmaceuticals' (NASDAQ:CNSP) Cash Burn Situation

CNS Pharmaceuticals, Inc. Receives Approval from Switzerland Ethics Committee for its Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme

AMMINISTRATORE DELEGATO

Gruppo dirigente

Membri del Consiglio di amministrazione

Analisi aziendale e situazione dei dati finanziari

Fonti dei dati

Modello di analisi e Snowflake

Metriche di settore e industriali

Fonti analitiche